World Journal of
Clinical Cases

World Journal of Clinical Cases

Contents

Contents

Contents

Contents

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Mohsen Khosravi, MD, Assistant Professor, Department of Psychiatry and Clinical Psychology, Zahedan University of Medical Sciences, Zahedan 9819713955, Iran. m.khosravi@zaums.ac.ir

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

   WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJCC* as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The *WJCC*'s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

How to select the quantitative magnetic resonance technique for subjects with fatty liver: A systematic review

You-Wei Li, Yang Jiao, Na Chen, Qiang Gao, Yu-Kun Chen, Yuan-Fang Zhang, Qi-Ping Wen, Zong-Ming Zhang

You-Wei Li, Yu-Kun Chen, Yuan-Fang Zhang, Qi-Ping Wen, Department of Radiology, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 100144, China

Yang Jiao, Department of Rehabilitation Psychology, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 100144, China

Na Chen, Department of Otorhinolaryngology, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 100144, China

Qiang Gao, Department of Gastroenterology and Hepatology, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 100144, China

Zong-Ming Zhang, Department of General Surgery, Beijing Electric Power Hospital, State Grid Corporation of China, Capital Medical University, Beijing 100073, China

Corresponding author: Zong-Ming Zhang, MD, PhD, Chief Doctor, Director, Professor, Department of General Surgery, Beijing Electric Power Hospital, State Grid Corporation of China, Capital Medical University, No. 1 Taipingqiaoxili, Fengtai District, Beijing 100073, China. zhangzongming@mail.tsinghua.edu.cn

Abstract

BACKGROUND

Early quantitative assessment of liver fat content is essential for patients with fatty liver disease. Mounting evidence has shown that magnetic resonance (MR) technique has high accuracy in the quantitative analysis of fatty liver, and is suitable for monitoring the therapeutic effect on fatty liver. However, many packaging methods and postprocessing functions have puzzled radiologists in clinical applications. Therefore, selecting a quantitative MR imaging technique for patients with fatty liver disease remains challenging.

AIM

To provide information for the proper selection of commonly used quantitative MR techniques to quantify fatty liver.

METHODS

We completed a systematic literature review of quantitative MR techniques for detecting fatty liver, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol. Studies were retrieved from PubMed,

Embase, and Cochrane Library databases, and their quality was assessed using the Quality Assessment of Diagnostic Studies criteria. The *Reference Citation Analysis* database (https://www.referencecitationanalysis.com) was used to analyze citation of articles which were included in this review.

RESULTS
Forty studies were included for spectroscopy, two-point Dixon imaging, and multiple-point Dixon imaging comparing liver biopsy to other imaging methods. The advantages and disadvantages of each of the three techniques and their clinical diagnostic performances were analyzed.

CONCLUSION
The proton density fat fraction derived from multiple-point Dixon imaging is a noninvasive method for accurate quantitative measurement of hepatic fat content in the diagnosis and monitoring of fatty liver progression.

Key Words: Fatty liver; Hepatic fat content; ^{1}H-magnetic resonance spectroscopy; Multiple-point Dixon imaging; Two-point Dixon imaging

Core Tip: This study focused on properly selecting commonly used quantitative magnetic resonance (MR) techniques to quantify fatty liver disease. We completed a systematic literature review of quantitative MR techniques for detecting fatty liver, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol. Three techniques including spectroscopy, two-point Dixon imaging, and multiple-point Dixon imaging, were compared. We found that proton density fat fraction derived from multiple-point Dixon imaging is a noninvasive method for accurate quantitative measurement of hepatic fat content. It can be used to diagnose fatty liver disease and monitor disease progression as well as treatment effects.

INTRODUCTION
Fatty liver refers to the excessive accumulation of triglycerides within the cytoplasm of hepatocytes. Increased fat deposition in hepatocytes can cause hepatocyte injury, inflammation, fibrosis, and eventually cirrhosis, with a high risk of liver failure and hepatocellular carcinoma[1]. Therefore, early quantitative assessment of hepatic fat content is essential for patients with fatty liver disease.

Liver biopsy is the gold standard for assessing hepatic fat content[2]. This may increase the chances of sampling error commonly encountered in livers with inhomogeneous fat distribution, because only a small fraction of the entire liver is sampled. Additionally, it can cause complications, such as bleeding, infection, and death. More importantly, this operation cannot be repeated and is not conducive for longitudinal monitoring of disease progression[3].

Ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are commonly used for noninvasive examination of fatty liver. Ultrasound is easy to perform. Quantitative measurements were performed using the attenuation and backscatter coefficients. However, its accuracy in staging fatty liver is low because the images are blurred by hepatic parenchymal structures and ultrasound beam is attenuated significantly by the fatty liver[4], especially in obese patients[5]. Additionally, ultrasound is highly operator-dependent and has low reproducibility[4]. CT evaluation of fatty liver is based on the absolute CT value of liver parenchyma or relative attenuation difference between liver parenchyma and spleen[6,7]. When the threshold was 42 Hounsfield units, the sensitivity and specificity for grade 2–3 fatty liver were 73% and 100%, respectively[8]. The energy spectrum of fat is similar to that of the liver parenchyma in dual-energy CT examination. Therefore, its accuracy in diagnosing fatty liver is lower than that of conventional CT[6]. Moreover, CT exposes patients to radiation and is thus not advisable for repeated use. Various MR techniques have been developed for the quantitative assessment of signal fat fraction (SFF) and/or proton density fat fraction (PDFF). SFF is defined as the signal from fat divided by the combined signal from fat and water. This is measured using fat-

suppressed techniques or chemical shift–encoded imaging (CSI) and MR spectroscopy (MRS) techniques [9]. This measurement is biased by one or more confounding factors. Once all confounding factors have been addressed, SFF is equivalent to PDFF[10]. PDFF, which can be measured with MRS or CSI, reflects the true fat content in tissue and thus, has become a reliable, accurate, and standardized MR-based biomarker for tissue fat accumulation. Mounting evidence has shown that MR has high accuracy in quantitatively analyzing fatty liver and can be repeated without radiation exposure[11-14]. However, many packaging methods and postprocessing functions have puzzled radiologists in clinical applications. This study compiled widespread data on MR techniques. This study aimed to provide information for properly selecting quantitative MR techniques to visualize the fatty liver.

MATERIALS AND METHODS

Data acquisition
A systematic review of the literature was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines[15]. Literature from 1984 to 2021 was searched in PubMed, Embase, and Cochrane Library. The *Reference Citation Analysis* database (https://www. referencecitationanalysis.com) was used to analyze citation of articles which were included in this review. Combined MeSH and free text were used as retrieval strategies (Supplementary Table 1). Only the studies published in English were included. To ensure literature saturation, we scrutinized the reference lists of the included studies. The inclusion criteria were as follows: (1) Studies limited to human participants; (2) Studies related to the principles of MR techniques or systemic review and meta-analysis for measuring hepatic fat content; and (3) Studies involving comparisons of MR techniques with other methods (liver biopsy, ultrasound, or CT) to measure hepatic fat content. Studies conducted on animals, those without full text, review papers, conference proceedings, and case reports were excluded. The studies were independently screened by two authors, and study selection was decided by consensus.

Assessment of study quality
Two authors used the Quality Assessment of Diagnostic Studies (QUADAS)-2 criteria in RevMan 5.4 for judging the risk of bias independently. Each study was given a low, high, or unclear risk of bias (Supplementary material) following QUADAS-2 guidance in the four domains. The signaling question 2 in the first domain was replaced by "Was the study design prospective or retrospective" because a retrospective study had a relatively higher risk of bias[16]. Any disagreements were resolved by a third author.

Data extraction
The following data were extracted: First author, publication year, study design, number of patients, mean age, studied etiology, data on MR techniques such as field strength and scan sequences, comparison, interval between MR methods and comparison, and study outcomes. If a study reported multiple MR methods, the data from the main modality was extracted.

Qualitative synthesis
The principles, main technical factors, advantages, and disadvantages of each method were summarized and evaluated. The results of the studies with an overall low and moderate risk of bias were used to analyze the diagnostic performance of one of the three methods.

RESULTS

Literature search results
Electronic search identified 633 studies. Of these, 467 studies were excluded after reviewing the titles, abstracts, and keywords of each study. Another 52 studies were excluded after reading full-text articles. Of the 114 included studies, 35 were related to MR techniques, and 39 were reviews and meta-analyses. Consequently, 40 studies were used for further analysis, including 20, 9, and 12 studies for spectroscopy two-point Dixon imaging, and multiple-point Dixon imaging compared with other methods, respectively (Figure 1). Detailed data extraction for each study is shown in Tables 1-3.

Quality assessment
The outcomes of risk of bias assessment in the 40 studies are summarized in Figure 2. The overall low risk of bias in the ^{1}H-MRS, two-point Dixon imaging, and multiple-point Dixon imaging groups was 50%, 55.5%, and 33.3%, respectively. Qualitative rather than quantitative synthesis was used in this study because of the high bias of included studies.

Table 1 Studies reporting on the measurement of the hepatic fat content with ¹H-magnetic resonance spectroscopy versus liver biopsy and other imaging methods

Ref.	Year	Study design	Age (year)	N	Etiology	Field strength sequence	Comparison	Interval	Results
Thomsen *et al*[22]	1994		48	14	Fatty liver	1.5 T. STEAM (TE = 34 ms)	Liver biopsy		$r = 0.897$; $P < 0.001$
Longo *et al*[26]	1995		45	29	Diffuse steatosis	1.5 T. PRESS (TE = 50–200 ms)	Liver biopsy		$r = 0.70$
Cowin *et al*[30]	2008		42	12	Steatosis	1.5 T. PRESS (TE = 30 ms)	Liver biopsy	6 wk	$r = 0.928$; $P < 0.0001$
Irwan *et al*[63]	2008	Prospective	47	10	Healthy volunteers	1.5 T. PRESS (TE = 30 ms)	Dual-echo imaging	One measurement session	$r = 0.927$. In the range 1%–10%, the MRI-determined the liver fat contents (corrected algorithm) are systematically higher, on average 4% (range: 2.1%–6.1%) than those obtained with MRS
Kim *et al*[64]	2008	Prospective	15.9 ± 5.3	28	Lean and obese	1.5 TPRESS (TE = 20 ms)	Two-Point Dixon		$r = 0.954$; $P < 0.001$
Borra *et al*[65]	2009	Prospective	62.8 ± 8.3	33	Type 2 diabetes	1.5 T. PRESS (TE = 25 ms)	IP/OP (Dixon)		$r = 0.959$–0.962; $P < 0.001$
Reeder *et al*[66]	2009	Prospective	49.0 ± 12	31	Suspected steatosis and unrelated reasons	1.5 T. PRESS (TE = 25 ms)	IDEAL		$r = 0.83 ± 0.05$; $P < 0.001$. Intercept (1.76 ± 0.76%; $P = 0.03$)
Zhong *et al*[31]	2009		50 ± 12	36	Fatty liver	3.0 T. PRESS (TE = 144 ms)	16-row multislice CT		$r = -0.461$; $P = 0.005$
Hu *et al*[67]	2010			16		3.0 T. PRESS (TE = 23 ms)	IDEAL		Slope = 0.90, intercept = 1.07%; $r^2 = 0.95$, $P < 0.001$
Roldan-Valadez *et al*[68]	2010		35	18	Steatosis	3.0 T	Liver biopsy		$r = 0.876$; $P ≤ 0.001$
Mehta *et al*[32]	2010		39.9	50	Steatosis	1.5 T. PRESS (TE = 135 ms)	Ultrasound		BMI > 30, sensitivity 96%; BMI ≤ 30, sensitivity 64%
Meisamy *et al*[23]	2011	Prospective	40	55		1.5 T. STEAM (TE = 10, 20, 30, 40, and 50 ms)	IDEAL		$r^2 = 0.99$
Georgoff *et al*[69]	2012	Prospective	50.6	52	Steatosis	3.0 T. PRESS (TE = 50 ms)	Liver biopsy	15 ± 9 d	Diagnostic accuracy was (AUC: 0.95; 95%CI: 0.89–1.0)
Kang *et al*[18]	2012	Prospective	54	56	Steatosis	1.5 T. STEAM (TE = 20, 30, 40, 50, and 60 ms)	Liver biopsy	1–28 d	$r = 0.95$
Parente *et al*[70]	2014	Prospective	54 ± 9	73	Nonalcoholic fatty liver disease	3.0 T. PRESS (TE = 40 ms)	Liver biopsy		$r = 0.767$; $P < 0.001$
Bashir *et al*[71]	2015	Prospective	55 ± 13.8	217	Various hepatic diseases	1.5 T. STEAM (TE = 12 ms)	Two-point Dixon		$r = 0.61$; $P < 0.001$
Kim *et al*[57]	2015		52.8 ± 14	42	Various hepatic diseases	3.0 T. STEAM (TE = 12, 24, 36, 48, and 72 ms)	In- and opposed-phase echo pairs		$r = 0.97$
Satkunasingham *et al*[72]	2015	Retrospective	57.8 (12–83)	156	Various hepatic diseases	3.0 T. STEAM (TE = 12, 24, 36, 48, and 72 ms)	MRI-PDFF		$r = 0.977$; $P < 0.001$
Rastogi *et al*[73]	2016	Retrospective	32.5	73	Steatosis	3.0 T. STEAM (TE = 15, 20, 25, 30, and 35	Biopsy and surgery	≤ 20 d	MRS correlated well with the histopathology results ($r = 0.882$). An accuracy of 96%

					ms)			and sensitivity of 94%
Kramer *et al*[6]	2017	Prospective	57 ± 5	50	Various hepatic diseases	1.5 T. STEAM (TE = 10, 20, 30, 40, and 50 ms)	PDFF	r^2 = 0.992; slope, 0.974; intercept, –0.943

MRS: Magnetic resonance spectroscopy; PDFF: Proton density fat fraction; TE: Echo time; BMI: Body mass index; CT: Computed tomography; Blank: No information; PRESS: Point-resolved spectroscopy; STEAM: Stimulated-echo acquisition mode.

Table 2 Studies reporting on the measurement of the hepatic fat content with in-phase and out-of-phase imaging versus liver biopsy and other imaging methods

Ref.	Year	Study design	Age (year)	N	Etiology	Field strength sequence	Comparison	Interval	Results
Fishbein e*t al*[35]	2005		47 ± 10	38	Various hepatic diseases	1.5 T. IP/OP (Dixon)	Biopsy	2 wk	r = 0.773, P < 0.001; Macrovesicular steatosis: r = 0.920, mixed steatosis: r = 0.605, P = 0.05
Kalra *et al* [74]	2009	Prospective	41 ± 9.2	10	Nonalcoholic fatty liver disease	1.5 T. IP/OP (Dixon)	Biopsy		Provides data on fat infiltration without information of hepatic fibrosis
Mennesson *et al*[41]	2009	Prospective	52.5	40	Various hepatic diseases	1.5 T. IP/OP (Dixon)	Biopsy	Same day	r = 0.852; P < 0.0001
Fischer *et al* [37]	2010	Prospective	66 ± 12	23	Various hepatic diseases	1.5 T IP/OP (Dixon)	Biopsy and surgery	≤ 10 d	r = 0.92; P < 0.0001
Pacifico *et al* [75]	2011	Case–control	7-16	25	Nonalcoholicfatty liver disease	1.5 T. Two-point Dixon	Biopsy	1–7 d	r = 0.883; P < 0.0001
Guaraldi *et al*[76]	2012	Observational pilot		16		1.5 T. IP/OP (Dixon)	Biopsy		r = 0.88; P < 0.0001
Koelblinger *et al*[77]	2012	Prospective	60.5	35	Various hepatic diseases	3.0 T. IP/OP (Dixon)	Biopsy		Uncorrected: r = 0.67, P < 0.001. Spleen correction: r = 0.85, P < 0.001
Rastogi *et al* [73]	2016	Retrospective	32.5	73	Steatosis	3.0 T. IP/OP (Dixon)	Biopsy and surgery	≤ 20 d	Dual-echo MRI correlated well with the histopathology results (r = 0.871). An accuracy of 95% and sensitivity of 97%
Bhat *et al*[78]	2017	Prospective	46	30	Steatosis	1.5 T. Two-point DIXON	Biopsy	1 wk	Good correlation between the MR estimation of liver fat and histological grading. 90% of patients had a fat content of less than 10%. The maximal fat content of 28% was observed in one patient

MRI: Magnetic resonance imaging; Blank: No information.

Findings of three MR methods

^{1}H-MRS-principle: ^{1}H-MRS measures the chemical composition of tissues. A signal from a region of interest (ROI) is Fourier transformed into an MR spectrum that displays various metabolites with unique frequencies. Triglycerides are composed of three fatty acid chains connected to a glycerol backbone; hence, at least six peaks can be resolved in the MRS spectrum. The water proton yields a single peak whose position in the spectrum may vary slightly depending on the temperature[17]. Liver SFF can be calculated as follows: $A_{fat}/(A_{fat} + A_{water}) \times 100\%$, where A_{fat} is the summation of lipid peak areas and A_{water} is the area under the water peak[18]. After T1 and T2 relaxation effects are corrected, spectroscopy-derived PDFF can be corrected[19,20].

Main technical factors-single-voxel technique *vs* multi-voxel technique: ^{1}H-MRS spectra can be obtained using single-voxel or multiple-voxel techniques. The single-voxel technique for sampling a voxel of interest with a high signal-to-noise ratio (SNR) is commonly applied in hepatic MRS measurements[19].

Main technical factors-PRESS *vs* stimulated-echo acquisition mode: The most commonly used techniques for ^{1}H-MRS are point-resolved spectroscopy (PRESS) and stimulated-echo acquisition mode (STEAM). PRESS is a spin-echo technique with a longer minimal echo time (TE) that allows for better

Table 3 Studies reporting on the measurement of the hepatic fat content with multiple-point Dixon imaging versus liver biopsy and other imaging methods

Ref.	Year	Study design	Age (year)	N	Etiology	Field strength sequence	Comparison	Interval	Results
Noureddin *et al*[79]	2013	Randomized		50	Nonalcoholic fatty liver disease	MRI-PDFF	MRS	0 and 24 wk	$r^2 = 0.98$; $P < 0.0001$
Idilman *et al* [28]	2013	Prospective	44.7 ± 13.1	70	Nonalcoholic fatty liver disease	1.5 T. IDEAL-IQ	Biopsy	14.5 d (0–259)	$r = 0.820$; The correlation of PDFF in mild hepatic steatosis was found to be better than that of moderate or severe steatosis ($r = 0.835$ and $r = 0.402$, respectively; $P = 0.003$)
Deng *et al* [51]	2014	Prospective	3–16	10	Nonalcoholic fatty liver disease	1.5 T. Multi-point Dixon	Biopsy		$r = 0.90$; $P = 0.0004$
Kukuk *et al* [59]	2015		51.7 ± 15.2	59	Liver disorders	3.0 T. Six echo-mDixon	Biopsy	≤ 6 wk	$r = 0.967$, $P < 0.001$. Slightly a higher hepatic fat contents than q Histo (mean difference 2.1% for 6E-mDixon and 1.9% for MRS)
Rehm *et al* [52]	2015	Prospective	13.3 ± 2 (11–22)	132	Healthy females	3.0 T. Multi-echo Dixon	STEAM (TE = 10, 15, 20, 25, and 30 ms)		$r = 0.96$
Schwimmer *et al*[80]	2015	Prospective	14	174	No steatosis and nonalcoholic fatty liver disease	3.0 T. Multi-echo Dixon	Biopsy	57 ± 51 d	$r = 0.725$; $P < 0.01$
Idilman *et al* [55]	2016	Retrospective	41.7 ± 14.6	19	Nonalcoholic fatty liver disease	1.5 T. DEAL-IQ	Biopsy		$r = 0.743$; $P < 0.001$
Hetterich *et al*[39]	2016	Prospective	57.2 ± 9.4	215		3.0 T. STEAM (TE = 12, 24, 36, 48, and 72 ms)	Multi-echo Dixon		$r = 0.96$; $P = 0.001$
Middleton *et al*[81]	2017	Randomized	51 ± 11	113	Nonalcoholic steatohepatitis	1.5 T or 3.0 T. Six echo-mDixon	Biopsy	51 d	$r = 0.80$; $P < 0.001$
Kang *et al* [46]	2018	Prospective	47.3 ± 14.9	29	NAFLD (34). Alcoholic liver disease (13). Liver cirrhosis (9)	3.0 T. mDIXON-Quant sequence	Biopsy	Same day	$r = 0.809$; $P < 0.001$
Pickhardt *et al*[82]	2018	Retrospective	54 ± 12	221		1.5 T or 3.0 T. MRI-PDFF	CT	0–158 mo	$r = 0.88$ (≤ 1 mo) substantially worsened with increasing time
Guo *et al*[83]	2020	PProspective	52.6 (22–83)	400	Healthy adults and older adults	3.0 T mDixon-Quant sequence	CT	Same day	$r = 0.79$; $P < 0.001$

MRS: Magnetic resonance spectroscopy; PDFF: Proton density fat fraction; TE: Echo time; BMI: Body mass index; CT: Computed tomography; Blank: No information; PRESS: Point-resolved spectroscopy; STEAM: Stimulated-echo acquisition mode.

visualization of metabolites with long T2 relaxation times. However, STEAM applies a 90°–90°–90° pulse and provides a shorter TE that is suitable for metabolites with short T2 relaxation times. PRESS has a higher SNR and is relatively insensitive to patient motion compared to STEAM, whereas STEAM is less affected by J-coupling and is generally preferred[21].

Main technical factors-correcting T1 and T2 effects: T1 and T2 values affect fat content measurement. In general, T1 relaxation times cause no trouble because the TR of MRS is much longer than the longest T1 of fat[22,23]. However, different T2 relaxation times may be problematic[24]. Both PRESS and STEAM sequences have a TE delay, causing spin-spin relaxation and decrease the signal[25]. Multiple spectroscopic acquisitions with different TEs are required to correct T2 values. If the spectra are acquired at a single TE, the sequence must use minimal TE to reduce T2 effects. Therefore, STEAM with shorter TE is recommended.

Main technical factors-ROI: The ROI was placed at the center of the right hepatic lobe to avoid vascular structures, bile ducts, and the liver edge[19].

Figure 1 Flowchart of the study selection. MR: Magnetic resonance.

Main technical factors-advantages: ^{1}H-MRS is an alternative to liver biopsy. It can accurately quantify fat content with high intra- or inter-individual reproducibility[26] and is not affected by hepatic iron deposition, inflammation, and fibrosis[18].

^{1}H-MRS is a noninvasive method for assessing hepatic lipid composition. Higher indices of hepatic fatty acid saturation and lower indices of unsaturation were observed in patients with obesity-related metabolic disease[27].

Main technical factors-disadvantages: ^{1}H-MRS requires technical expertise for its acquisition and analysis[28]. ^{1}H-MRS introduced sampling errors, especially in the liver with nonhomogeneous fat distribution, because fat is measured in the ROI rather than in the entire liver[29].

Hepatic fat showed multiple peaks on MR spectroscopy. The main lipid peak is at approximately 0.9–2.75 ppm and two unsolved lipid resonances at 4.2 and 5.3 ppm overlapping with the water peak, leading to quantification errors[19].

Diagnostic performance-^{1}H-MRS *vs* liver biopsy: Five studies with an overall low risk of bias were used to evaluate the diagnostic performance of ^{1}H-MRS[22,26,30-32]. These studies showed that ^{1}H-MRS strongly correlated with the degree of hepatic steatosis on liver biopsy ($r = 0.767–0.959$). The sensitivity and specificity for ^{1}H-MRS diagnosis of hepatic fat content of 5% or more were 94.4% and 89.5%, respectively[18].

Diagnostic performance-^{1}H-MRS *vs* other imaging methods: ^{1}H-MRS is considered the gold standard for other imaging methods to quantify hepatic fat content. One study[32] demonstrated that ultrasound detected liver fat in 82% of cases, measurable by ^{1}H-MRS. Zhong *et al*[31] compared CT with ^{1}H-MRS to quantitatively assess hepatic fat content and found that ^{1}H-MRS correlated with the CT liver/spleen ratio ($r = –0.461$).

Two-point Dixon technique

Principle: Two-point Dixon technique produces in-phase (IP) and out-of-phase (OP) images using two acquisitions[33,34]. The signal intensity (SI) on IP images is the sum of water and fat signals within a voxel, whereas that on OP images is the difference between water and fat signals. Thus, SFF can be calculated using the following formula: $SFF = [(SI_{IP} – SI_{OP})/2SI_{IP}] \times 100$, where SI_{IP} is the SI in a voxel on the IP image and SI_{OP} is the SI on the OP image[35].

Main technical factors-SE *vs* gradient-recalled echo: Gradient-recalled echo (GRE) is routinely used for hepatic fat estimation. Since the GRE sequence is susceptible to the motion and paramagnetic effects of iron, Dixon used the SE sequence instead of the GRE sequence for CSI. A three-point Dixon method, which introduced a third echo to correct phase errors, was required to overcome long scan time and sensitivity to magnetic field inhomogeneities[34,36].

Figure 2 Risk-of-bias and applicability concerns graph. A: Studies for [1]H-magnetic resonance spectroscopy *vs* liver biology and other imaging methods in measuring hepatic fat content; B: Studies for in-phase and out-of-phase imaging *vs* liver biology and other imaging methods in measuring hepatic fat content; C: Studies for multiple-point Dixon imaging *vs* liver biology and other imaging methods in measuring hepatic fat content.

Main technical factors-2D *vs* 3D: IP and OP images are typically obtained in 2D acquisitions with multiple breath-holds for nonvolumetric quantification of hepatic fat. The 3D GRE sequence provided volumetric coverage of the liver but increased the post-processing time[37].

Main technical factors-ROI: ROIs were drawn at anatomically matched locations on the hepatic parenchyma on paired sequences, using a co-registration tool to exclude vessels, bile ducts, motion artifacts, and partial volume effects. Two of the 12 circular ROIs were placed in the right liver and two in the left liver above, below, and at the level of the porta hepatis[38].

Main technical factors-advantages: This technique could be used with all types of MR scanners (0.5T-3T). Both IP and OP images were acquired in the same breath-hold, and all imaging parameters, except TE, were similar. Therefore, the SI differences between the two images were based only on parallel, opposing water, and fat protons. The quality of the images was not affected by phase-related effects owing to amplitude imaging without phase information[33].

Main technical factors-disadvantages: The IP and OP images contained T1, T2, and T2*. These estimate the hepatic fat content inaccurately, especially for the liver with a fat content lower than 5%[38,39]. Because the liver SFF is within the dynamic range of 0%–50%[18], when the hepatic fat content was > 50%, the dominant constituent in a voxel is ambiguous on IP and OP images. This require phase-sensitive processing or a dual flip angle (20°and 70°) for removal[40].

The SFF derived from the IP and OP images assumes that water and fat have a single resonance frequency. In fact, this was not true for fat. Therefore, SFF based on IP and OP images is intrinsically incorrect[33].

Diagnostic performance: The sensitivity and specificity of SFF for diagnosing hepatic fat content > 20% are 96% and 93%, respectively[41]. However, a sensitivity of 89% and specificity of 82% were observed for an SFF of 1.8%[37].

Multiple-point Dixon technique

Principle: Multiple-point Dixon acquires data from more than three echoes and provides images with both the magnitude and phase information of the echoes. This method addresses many confounding factors and yields accurate PDFF measurements. Simultaneously, transverse relaxation rate maps for

measuring the iron content are also obtained[33,34,40]. The whole-liver PDFF was measured by averaging PDFF values from multiple regions in different parts of the liver. However, an optimal ROI-based sampling strategy has not yet been established[42].

Main technical factors-correcting T1 and T2* effects: In general, a long TR or a low flip angle in spoiled GRE acquisitions is used to minimize T1 bias. Echoes were acquired at three or more nominally OP and IP TEs to minimize T2* interference, especially the IDEAL-IQ sequence using a 6-echo 3-point Dixon method[28,33].

Main technical factors-noise and eddy: The noise bias originated from the skewed noise distribution in areas with a low signal during the magnitude operation. It significantly affects low-fat regions and makes the diagnosis of mild steatosis difficult. Noise bias can be mitigated using a hybrid complex/magnitude reconstruction[43].

Eddy currents were generated during rapid gradient switches at multiple TEs, which led to a phase shift and adversely affected the complex-based PDFF. This can be addressed by acquiring additional calibration data[44].

Main technical factors-fat spectral complexity: The fat spectrum consisted of multiple peaks that interfered with each other, as well as water, and made the PDFF incorrect. Multiple spectral models are required to address these multifrequency effects[45].

Main technical factors-ROI: It is recommended to select one to three ROIs *per* Couinaud segment, with the first ROI in each segment as centrally as possible and the remaining two on the same slice. ROI placement on the source images must avoid vessels, artifacts, and the edge of the liver.

Main technical factors-advantages: Multipoint Dixon imaging can be completed within a single breath-hold[46]. MRI-PDFF calculation used both the phase and magnitude data of the MR signal to measure the fat concentration in the range of 0%–100%[47]. The field strength and imaging manufacturer had negligible effects on the measurements[48].

Main technical factors-disadvantages: The accuracy of MRI-PDFF measurements is affected by fibrosis and severe steatosis[49]. The correlation between liver biopsy findings and MRI-PDFF was weaker in patients with moderate or severe hepatic steatosis than in those with milder forms[50].

Diagnostic performance: The sensitivity and specificity of MRI-PDFF were 83% and 89% for LS ≥ G2, and 79% and 89% for LS = G3, respectively[12]. An excellent correlation (r = 0.96–0.984)[28,51,52] with ^{1}H-MRS has also been shown and confirmed by a previous meta-analysis (r = 0.96)[48].

DISCUSSION

MR techniques have emerged as reliable tools for the noninvasive estimation of hepatic fat content. This systematic review compared three common MR techniques: ^{1}H-MRS, two-point Dixon imaging, and multiple-point Dixon imaging. These techniques have the same basic physical principles based on the chemical shift between the main peak of fat and that of water[33].

Before 2012, many studies used ^{1}H-MRS and two-point Dixon imaging to measure hepatic fat content. The liver SFF calculated from ^{1}H-MRS was not affected by iron deposition, fibrosis, or coexisting pathology, and provided accurate quantification of liver fat[19,53], especially MRS-PDFF[20]. Therefore, ^{1}H-MRS is commonly used as a reference for other imaging techniques to measure hepatic fat content. However, expensive and complex post-processing procedures as well as only providing accurate data of liver fat content from small parenchymal regions, especially single-voxel ^{1}H-MRS, hampered its widespread clinical application. Moreover, ^{1}H-MRS is not available at every institution. Chemical shift MR imaging can visualize the regional distribution of intrahepatic lipids. The IP and OP images derived from the two-point Dixon technique are simple approaches. This technique requires several data sets with different TEs to calculate the fat content, which contains T1 and T2* effects; therefore, it evaluates the hepatic fat content inaccurately, especially for livers with less than 5% fat[39]. Springer[54] used additional individual time-consuming T1 and T2* measurements to correct the measured intrahepatic lipids; however, most measurements are not applicable in time-restricted examination protocols. This method also measures liver fat concentration within the dynamic range of 0%–50%[18].

Aside from measuring the liver fat concentration in the range of 0%–100%, the PDFF derived from multiple-point Dixon imaging mitigates confounding factors, such as T1, T2*, lipid spectral complex, noise, and eddy current, and has been successfully applied to quantify liver fat. It has been extensively used for detecting and grading hepatic steatosis, especially for differentiating moderate/severe steatosis from mild/no hepatic steatosis[55] accurately. This is due to its good correlation with histopathology and ^{1}H-MRS measurements[12,56] as well as the shorter acquisition time compared with MRS[3,10,12,28,57]. Concurrent with PDFF acquisition, an R2* (1/T2*) map might also be formed, which could measure the iron concentration in the liver[58]. Additionally, PDFF was independent of field strength,

scanner platform, and specific scanning parameters. However, this method yields a slightly higher hepatic fat content than liver histology[59] and the accuracy of measurements could be affected by fibrosis and severe steatosis. It lacked the power to detect the changes in non-alcoholic fatty liver disease (NAFLD) such as inflammation or fibrosis[13,47].

Recent studies have also shown that MR elastography and T1-T2 mapping can be useful in detecting hepatic inflammatory and fibrotic changes[13,60,61]. Therefore, the multiparametric MRI protocol may be helpful in liver tissue characterization and in risk stratification and therapeutic management of patients with NAFLD.

How do we choose each technique in daily practice? For epidemiological studies, MR and CT are unsuitable because of the expensive and time-consuming nature of MR and radiation damage from CT. Here, ultrasound is preferred. For clinical studies, especially follow-up or assessment of treatment efficacy, two-point Dixon and multiple-point Dixon imaging are preferred because of their subjective and robust characteristics. However, CT can be selected for shorter follow-up in primary or secondary care where there is no MR machine. MRS is the most accurate noninvasive technique and is a good standard in research studies, although its accuracy depends on expertise and the result is difficult to explain. Multiparametric MRI protocols, including MR elastography and T1-T2 mapping may be useful for stratification and therapeutic management of patients with NAFLD.

This study has several limitations. First, this review may have potential publication bias because gray literature and non-English language literature were not retrieved. Second, the overall moderate and high risks of bias in the ^{1}H-MRS, two-point Dixon imaging, and multiple-point Dixon imaging groups were 50%, 45.5%, and 66.7%, respectively. Therefore, qualitative methods other than quantitative synthesis were used. The diagnostic accuracy of each method requires further investigation through a meta-analysis. Third, less commonly used methods for quantitative analysis of hepatic fat content were not included in this review. These include fat-selective imaging with spectral-spatial excitation, which requires a homogenous static magnetic field for optimal spectral-spatial excitation and is relatively sensitive to breathing artifacts[54,62].

CONCLUSION

PDFF derived from multiple-point Dixon imaging is a noninvasive method that provides an accurate, quantitative measurement of hepatic fat content. It can be used clinically to diagnose fatty liver and follow-up the progression of the disease and treatment effect.

ARTICLE HIGHLIGHTS

Research background

Fatty liver can cause hepatocyte injury, inflammation, fibrosis, and eventually cirrhosis, with a high risk for liver failure and hepatocellular carcinoma. Early quantitative assessment of liver fat content is essential for patients with fatty liver disease.

Research motivation

Mounting evidence has shown that magnetic resonance (MR) technique has high accuracy in the quantitative analysis of fatty liver disease. However, many packaging methods and postprocessing functions have puzzled radiologists in clinical applications. Hence, selecting quantitative MR imaging (MRI) for patients with fatty liver disease is challenging.

Research objectives

To provide information for the proper selection of commonly used quantitative MR techniques to quantify fatty liver.

Research methods

A systematic review of the literature from 1983 to May 2021 using PubMed, Embase, and Cochrane Library was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Research results

A total of 114 articles were included, including 35 articles on MR techniques for measurement of hepatic fat content, 39 articles on reviews and meta-analysis, and 40 studies for further qualitative analysis. Because the overall moderate and high risk of bias in the 40 studies was approximately 50.0%, qualitative synthesis other than quantitative synthesis was used in this systematic review. The principle, main technical factors, advantages, and disadvantages of ^{1}H-MR spectroscopy, two-point Dixon

imaging, and multiple-point Dixon imaging, as well as their clinical diagnostic performance were summarized and analyzed.

Research conclusions

Proton density fat fraction (PDFF) derived from multiple-point Dixon imaging is a noninvasive method that provides an accurate, quantitative measurement of hepatic fat content.

Research perspectives

The accuracy of the PDFF derived from multiple-point Dixon imaging can be affected by fibrosis and severe steatosis. Therefore, the multiparametric MRI protocol might be helpful in liver tissue character-ization and thereby in the risk stratification and therapeutic management of patients with non-alcoholic fatty liver disease.

ACKNOWLEDGEMENTS

FOOTNOTES

ORCID number: You-Wei Li 0000-0002-3996-7919; Yang Jiao 0000-0002-7139-4372; Na Chen 0000-0002-4672-5598; Qiang Gao 0000-0002-2753-5190; Yu-Kun Chen 0000-0001-6887-4191; Yuan-Fang Zhang 0000-0002-1784-1071; Qi-Ping Wen 0000-0003-4293-3928; Zong-Ming Zhang 0000-0002-0797-7100.

REFERENCES

1   **Chalasani N**, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018; **67**: 328-357 [PMID: 28714183 DOI: 10.1002/hep.29367]

2   **Boyd A**, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. *Frontline Gastroenterol* 2020; **11**: 40-47 [PMID: 31885839 DOI: 10.1136/flgastro-2018-101139]

3   **Jayakumar S**, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in

patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. *J Hepatol* 2019; **70**: 133-141 [PMID: 30291868 DOI: 10.1016/j.jhep.2018.09.024]

4   **Ozturk A**, Grajo JR, Gee MS, Benjamin A, Zubajlo RE, Thomenius KE, Anthony BW, Samir AE, Dhyani M. Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. *Ultrasound Med Biol* 2018; **44**: 2461-2475 [PMID: 30232020 DOI: 10.1016/j.ultrasmedbio.2018.07.019]

5   **Starekova J**, Reeder SB. Liver fat quantification: where do we stand? *Abdom Radiol (NY)* 2020; **45**: 3386-3399 [PMID: 33025153 DOI: 10.1007/s00261-020-02783-1]

6   **Kramer H**, Pickhardt PJ, Kliewer MA, Hernando D, Chen GH, Zagzebski JA, Reeder SB. Accuracy of Liver Fat Quantification With Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR Spectroscopy. *AJR Am J Roentgenol* 2017; **208**: 92-100 [PMID: 27726414 DOI: 10.2214/AJR.16.16565]

7   **Hahn L**, Reeder SB, Muñoz del Rio A, Pickhardt PJ. Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis. *AJR Am J Roentgenol* 2015; **205**: 1167-1172 [PMID: 26587921 DOI: 10.2214/AJR.15.14724]

8   **Li Q**, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. *World J Hepatol* 2018; **10**: 530-542 [PMID: 30190781 DOI: 10.4254/wjh.v10.i8.530]

9   **Bray TJ**, Chouhan MD, Punwani S, Bainbridge A, Hall-Craggs MA. Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. *Br J Radiol* 2018; **91**: 20170344 [PMID: 28936896 DOI: 10.1259/bjr.20170344]

10   **Reeder SB**, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. *J Magn Reson Imaging* 2012; **36**: 1011-1014 [PMID: 22777847 DOI: 10.1002/jmri.23741]

11   **Zhang QH**, Zhao Y, Tian SF, Xie LH, Chen LH, Chen AL, Wang N, Song QW, Zhang HN, Xie LZ, Shen ZW, Liu AL. Hepatic fat quantification of magnetic resonance imaging whole-liver segmentation for assessing the severity of nonalcoholic fatty liver disease: comparison with a region of interest sampling method. *Quant Imaging Med Surg* 2021; **11**: 2933-2942 [PMID: 34249624 DOI: 10.21037/qims-20-989]

12   **Qu Y**, Li M, Hamilton G, Zhang YN, Song B. Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: a meta-analysis. *Eur Radiol* 2019; **29**: 5180-5189 [PMID: 30877459 DOI: 10.1007/s00330-019-06071-5]

13   **Erden A**, Kuru Öz D, Peker E, Kul M, Özalp Ateş FS, Erden İ, İdilman R. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction. *Diagn Interv Radiol* 2021; **27**: 7-14 [PMID: 33290237 DOI: 10.5152/dir.2020.19654]

14   **Zheng D**, Guo Z, Schroder PM, Zheng Z, Lu Y, Gu J, He X. Accuracy of MR Imaging and MR Spectroscopy for Detection and Quantification of Hepatic Steatosis in Living Liver Donors: A Meta-Analysis. *Radiology* 2017; **282**: 92-102 [PMID: 27479639 DOI: 10.1148/radiol.2016152571]

15   **Moher D**, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**: 1 [PMID: 25554246 DOI: 10.1186/2046-4053-4-1]

16   **De Visschere PJL**, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, Maurer T, Hadaschik BA, Lecouvet FE, Giannarini G, Fanti S. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. *Eur Urol Oncol* 2019; **2**: 47-76 [PMID: 30929846 DOI: 10.1016/j.euo.2018.09.010]

17   **Peterson P**, Trinh L, Månsson S. Quantitative ^{1}H MRI and MRS of fatty acid composition. *Magn Reson Med* 2021; **85**: 49-67 [PMID: 32844500 DOI: 10.1002/mrm.28471]

18   **Kang BK**, Yu ES, Lee SS, Lee Y, Kim N, Sirlin CB, Cho EY, Yeom SK, Byun JH, Park SH, Lee MG. Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. *Invest Radiol* 2012; **47**: 368-375 [PMID: 22543969 DOI: 10.1097/RLI.0b013e31824baff3]

19   **Pasanta D**, Htun KT, Pan J, Tungjai M, Kaewjaeng S, Kim H, Kaewkhao J, Kothan S. Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. *Diagnostics (Basel)* 2021; **11** [PMID: 34067193 DOI: 10.3390/diagnostics11050842]

20   **Runge JH**, Smits LP, Verheij J, Depla A, Kuiken SD, Baak BC, Nederveen AJ, Beuers U, Stoker J. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. *Radiology* 2018; **286**: 547-556 [PMID: 28915103 DOI: 10.1148/radiol.2017162931]

21   **Hamilton G**, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, Patton HM, Lavine JE, Sirlin CB. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. *J Magn Reson Imaging* 2009; **30**: 145-152 [PMID: 19557733 DOI: 10.1002/jmri.21809]

22   **Thomsen C**, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. *Magn Reson Imaging* 1994; **12**: 487-495 [PMID: 8007779 DOI: 10.1016/0730-725x(94)92543-7]

23   **Meisamy S**, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, Yu H, Brittain JH, Reeder SB. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. *Radiology* 2011; **258**: 767-775 [PMID: 21248233 DOI: 10.1148/radiol.10100708]

24   **Dieckmeyer M**, Ruschke S, Cordes C, Yap SP, Kooijman H, Hauner H, Rummeny EJ, Bauer JS, Baum T, Karampinos DC. The need for T_2 correction on MRS-based vertebral bone marrow fat quantification: implications for bone marrow fat fraction age dependence. *NMR Biomed* 2015; **28**: 432-439 [PMID: 25683154 DOI: 10.1002/nbm.3267]

25   **Gajdošík M**, Chmelík M, Just-Kukurová I, Bogner W, Valkovič L, Trattnig S, Krššák M. In vivo relaxation behavior of liver compounds at 7 Tesla, measured by single-voxel proton MR spectroscopy. *J Magn Reson Imaging* 2014; **40**: 1365-1374 [PMID: 24222653 DOI: 10.1002/jmri.24489]

26   **Longo R**, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Crocè LS, Grigolato P, Paoletti S, de Bernard B. Proton MR spectroscopy in quantitative *in vivo* determination of fat content in human liver steatosis. *J Magn Reson Imaging* 1995; **5**: 281-285 [PMID: 7633104 DOI: 10.1002/jmri.1880050311]

27   **Willis SA**, Bawden SJ, Malaikah S, Sargeant JA, Stensel DJ, Aithal GP, King JA. The role of hepatic lipid composition in obesity-related metabolic disease. *Liver Int* 2021; **41**: 2819-2835 [PMID: 34547171 DOI: 10.1111/liv.15059]

28   **Idilman IS**, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, Celik A, Bahar K, Karcaaltincaba M. Hepatic steatosis: quantification by proton density fat fraction with MR imaging *vs* liver biopsy. *Radiology* 2013; **267**: 767-775 [PMID: 23382293 DOI: 10.1148/radiol.13121360]

29   **Haus JM**, Solomon TP, Kelly KR, Fealy CE, Kullman EL, Scelsi AR, Lu L, Pagadala MR, McCullough AJ, Flask CA, Kirwan JP. Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. *J Clin Endocrinol Metab* 2013; **98**: E1181-E1188 [PMID: 23616151 DOI: 10.1210/jc.2013-1229]

30   **Cowin GJ**, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, Purdie DM, Clouston AD, Powell EE, Galloway GJ. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. *J Magn Reson Imaging* 2008; **28**: 937-945 [PMID: 18821619 DOI: 10.1002/jmri.21542]

31   **Zhong L**, Chen JJ, Chen J, Li L, Lin ZQ, Wang WJ, Xu JR. Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. *J Dig Dis* 2009; **10**: 315-320 [PMID: 19906112 DOI: 10.1111/j.1751-2980.2009.00402.x]

32   **Mehta SR**, Thomas EL, Patel N, Crofton ME, McCarthy J, Eliahoo J, Morin SX, Fitzpatrick J, Durighel G, Goldstone AP, Johnston DG, Bell JD, Taylor-Robinson SD. Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification. *Hepatol Res* 2010; **40**: 399-406 [PMID: 20236356 DOI: 10.1111/j.1872-034X.2009.00620.x]

33   **Hong CW**, Fazeli Dehkordy S, Hooker JC, Hamilton G, Sirlin CB. Fat Quantification in the Abdomen. *Top Magn Reson Imaging* 2017; **26**: 221-227 [PMID: 29176468 DOI: 10.1097/RMR.0000000000000141]

34   **van Vucht N**, Santiago R, Lottmann B, Pressney I, Harder D, Sheikh A, Saifuddin A. The Dixon technique for MRI of the bone marrow. *Skeletal Radiol* 2019; **48**: 1861-1874 [PMID: 31309243 DOI: 10.1007/s00256-019-03271-4]

35   **Fishbein M**, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. *J Clin Gastroenterol* 2005; **39**: 619-625 [PMID: 16000931 DOI: 10.1097/00004836-200508000-00012]

36   **Singh D**, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. *Indian J Endocrinol Metab* 2013; **17**: 990-995 [PMID: 24381873 DOI: 10.4103/2230-8210.122606]

37   **Fischer MA**, Nanz D, Reiner CS, Montani M, Breitenstein S, Leschka S, Alkadhi H, Stolzmann P, Marincek B, Scheffel H. Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat-signal separation in liver-fat quantification: comparison to liver biopsy. *Invest Radiol* 2010; **45**: 465-470 [PMID: 20479652 DOI: 10.1097/RLI.0b013e3181da1343]

38   **Bahl M**, Qayyum A, Westphalen AC, Noworolski SM, Chu PW, Ferrell L, Tien PC, Bass NM, Merriman RB. Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. *Radiology* 2008; **249**: 160-166 [PMID: 18796674 DOI: 10.1148/radiol.2491071375]

39   **Hetterich H**, Bayerl C, Peters A, Heier M, Linkohr B, Meisinger C, Auweter S, Kannengießer SA, Kramer H, Ertl-Wagner B, Bamberg F. Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population. *Eur Radiol* 2016; **26**: 1895-1904 [PMID: 26340812 DOI: 10.1007/s00330-015-3966-y]

40   **Eskreis-Winkler S**, Corrias G, Monti S, Zheng J, Capanu M, Krebs S, Fung M, Reeder S, Mannelli L. IDEAL-IQ in an oncologic population: meeting the challenge of concomitant liver fat and liver iron. *Cancer Imaging* 2018; **18**: 51 [PMID: 30541635 DOI: 10.1186/s40644-018-0167-3]

41   **Mennesson N**, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec JY, Pilleul F. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. *J Comput Assist Tomogr* 2009; **33**: 672-677 [PMID: 19820490 DOI: 10.1097/RCT.0b013e318199d883]

42   **Vu KN**, Gilbert G, Chalut M, Chagnon M, Chartrand G, Tang A. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes. *J Magn Reson Imaging* 2016; **43**: 1090-1099 [PMID: 26536609 DOI: 10.1002/jmri.25083]

43   **Liu CY**, McKenzie CA, Yu H, Brittain JH, Reeder SB. Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. *Magn Reson Med* 2007; **58**: 354-364 [PMID: 17654578 DOI: 10.1002/mrm.21301]

44   **Reeder SB**, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. *J Magn Reson Imaging* 2011; **34**: 729-749 [PMID: 22025886 DOI: 10.1002/jmri.22775]

45   **Hamilton G**, Yokoo T, Bydder M, Cruite I, Schroeder ME, Sirlin CB, Middleton MS. In vivo characterization of the liver fat ¹H MR spectrum. *NMR Biomed* 2011; **24**: 784-790 [PMID: 21834002 DOI: 10.1002/nbm.1622]

46   **Kang BK**, Kim M, Song SY, Jun DW, Jang K. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders: validation with MRS and histology. *Br J Radiol* 2018; **91**: 20170378 [PMID: 29022777 DOI: 10.1259/bjr.20170378]

47   **Caussy C**, Reeder SB, Sirlin CB, Loomba R. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. *Hepatology* 2018; **68**: 763-772 [PMID: 29356032 DOI: 10.1002/hep.29797]

48   **Yokoo T**, Serai SD, Pirasteh A, Bashir MR, Hamilton G, Hernando D, Hu HH, Hetterich H, Kühn JP, Kukuk GM, Loomba R, Middleton MS, Obuchowski NA, Song JS, Tang A, Wu X, Reeder SB, Sirlin CB; RSNA-QIBA PDFF Biomarker Committee. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. *Radiology* 2018; **286**: 486-498 [PMID: 28892458 DOI: 10.1148/radiol.2017170550]

49   **Lee SJ**, Kim SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. *Expert Rev Gastroenterol Hepatol* 2019; **13**: 523-530 [PMID: 31018719 DOI: 10.1080/17474124.2019.1608820]

50   **Lv S**, Jiang S, Liu S, Dong Q, Xin Y, Xuan S. Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. *J Clin Transl Hepatol* 2018; **6**: 217-221 [PMID: 29951367 DOI: 10.14218/JCTH.2018.00021]

51   **Deng J**, Fishbein MH, Rigsby CK, Zhang G, Schoeneman SE, Donaldson JS. Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. *Pediatr Radiol* 2014; **44**: 1379-1387 [PMID:

24840769 DOI: 10.1007/s00247-014-3024-y]

52   **Rehm JL**, Wolfgram PM, Hernando D, Eickhoff JC, Allen DB, Reeder SB. Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. *Eur Radiol* 2015; **25**: 2921-2930 [PMID: 25916386 DOI: 10.1007/s00330-015-3724-1]

53   **Thiagarajan P**, Bawden SJ, Aithal GP. Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy. *J Clin Med* 2021; **10** [PMID: 33562284 DOI: 10.3390/jcm10040632]

54   **Springer F**, Machann J, Schwenzer NF, Ballweg V, Würslin C, Schneider JH, Fritsche A, Claussen CD, Schick F. Quantitative assessment of intrahepatic lipids using fat-selective imaging with spectral-spatial excitation and in-/opposed-phase gradient echo imaging techniques within a study population of extremely obese patients: feasibility on a short, wide-bore MR scanner. *Invest Radiol* 2010; **45**: 484-490 [PMID: 20479651 DOI: 10.1097/RLI.0b013e3181df2afb]

55   **Idilman IS**, Keskin O, Celik A, Savas B, Elhan AH, Idilman R, Karcaaltincaba M. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS *vs* liver histology in non-alcoholic fatty liver disease. *Acta Radiol* 2016; **57**: 271-278 [PMID: 25855666 DOI: 10.1177/0284185115580488]

56   **Tang A**, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. *Radiology* 2013; **267**: 422-431 [PMID: 23382291 DOI: 10.1148/radiol.12120896]

57   **Kim KY**, Song JS, Kannengiesser S, Han YM. Hepatic fat quantification using the proton density fat fraction (PDFF): utility of free-drawn-PDFF with a large coverage area. *Radiol Med* 2015; **120**: 1083-1093 [PMID: 25952293 DOI: 10.1007/s11547-015-0545-x]

58   **Henninger B**, Plaikner M, Zoller H, Viveiros A, Kannengiesser S, Jaschke W, Kremser C. Performance of different Dixon-based methods for MR liver iron assessment in comparison to a biopsy-validated R2∗ relaxometry method. *Eur Radiol* 2021; **31**: 2252-2262 [PMID: 32965571 DOI: 10.1007/s00330-020-07291-w]

59   **Kukuk GM**, Hittatiya K, Sprinkart AM, Eggers H, Gieseke J, Block W, Moeller P, Willinek WA, Spengler U, Trebicka J, Fischer HP, Schild HH, Träber F. Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. *Eur Radiol* 2015; **25**: 2869-2879 [PMID: 25903702 DOI: 10.1007/s00330-015-3703-6]

60   **Pavlides M**, Banerjee R, Tunnicliffe EM, Kelly C, Collier J, Wang LM, Fleming KA, Cobbold JF, Robson MD, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. *Liver Int* 2017; **37**: 1065-1073 [PMID: 27778429 DOI: 10.1111/liv.13284]

61   **Besutti G**, Valenti L, Ligabue G, Bassi MC, Pattacini P, Guaraldi G, Giorgi Rossi P. Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review. *Liver Int* 2019; **39**: 1521-1534 [PMID: 30972903 DOI: 10.1111/liv.14118]

62   **Machann J**, Thamer C, Schnoedt B, Stefan N, Haring HU, Claussen CD, Fritsche A, Schick F. Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. *Magn Reson Med* 2006; **55**: 913-917 [PMID: 16506186 DOI: 10.1002/mrm.20825]

63   **Irwan R**, Edens MA, Sijens PE. Assessment of the variations in fat content in normal liver using a fast MR imaging method in comparison with results obtained by spectroscopic imaging. *Eur Radiol* 2008; **18**: 806-813 [PMID: 17999066 DOI: 10.1007/s00330-007-0801-0]

64   **Kim H**, Taksali SE, Dufour S, Befroy D, Goodman TR, Petersen KF, Shulman GI, Caprio S, Constable RT. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL. *Magn Reson Med* 2008; **59**: 521-527 [PMID: 18306404 DOI: 10.1002/mrm.21561]

65   **Borra RJ**, Salo S, Dean K, Lautamäki R, Nuutila P, Komu M, Parkkola R. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. *Radiology* 2009; **250**: 130-136 [PMID: 19017926 DOI: 10.1148/radiol.2501071934]

66   **Reeder SB**, Robson PM, Yu H, Shimakawa A, Hines CD, McKenzie CA, Brittain JH. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. *J Magn Reson Imaging* 2009; **29**: 1332-1339 [PMID: 19472390 DOI: 10.1002/jmri.21751]

67   **Hu HH**, Kim HW, Nayak KS, Goran MI. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. *Obesity (Silver Spring)* 2010; **18**: 841-847 [PMID: 19834463 DOI: 10.1038/oby.2009.352]

68   **Roldan-Valadez E**, Favila R, Martínez-López M, Uribe M, Ríos C, Méndez-Sánchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. *J Hepatol* 2010; **53**: 732-737 [PMID: 20594607 DOI: 10.1016/j.jhep.2010.04.018]

69   **Georgoff P**, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, Kottilil S, Morse C, Dodd L, Kleiner D, Hadigan C. Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. *AJR Am J Roentgenol* 2012; **199**: 2-7 [PMID: 22733887 DOI: 10.2214/AJR.11.7384]

70   **Parente DB**, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, Campos CF, Eiras-Araujo AL, do Brasil PE, Garteiser P, Gomes MB, de Mello Perez R. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? *PLoS One* 2014; **9**: e112574 [PMID: 25426708 DOI: 10.1371/journal.pone.0112574]

71   **Bashir MR**, Zhong X, Nickel MD, Fananapazir G, Kannengiesser SA, Kiefer B, Dale BM. Quantification of hepatic steatosis with a multistep adaptive fitting MRI approach: prospective validation against MR spectroscopy. *AJR Am J Roentgenol* 2015; **204**: 297-306 [PMID: 25615751 DOI: 10.2214/AJR.14.12457]

72   **Satkunasingham J**, Besa C, Bane O, Shah A, de Oliveira A, Gilson WD, Kannengiesser S, Taouli B. Liver fat quantification: Comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy. *Eur J Radiol* 2015; **84**: 1452-1458 [PMID: 26047820 DOI: 10.1016/j.ejrad.2015.05.001]

73   **Rastogi R**, Gupta S, Garg B, Vohra S, Wadhawan M, Rastogi H. Comparative accuracy of CT, dual-echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors. *Indian J Radiol Imaging* 2016; **26**: 5-14

[PMID: 27081218 DOI: 10.4103/0971-3026.178281]

74   **Kalra N**, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, Singh P, Khandelwal N. Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). *Ann Hepatol* 2009; **8**: 21-25 [PMID: 19221529]

75   **Pacifico L**, Martino MD, Catalano C, Panebianco V, Bezzi M, Anania C, Chiesa C. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. *World J Gastroenterol* 2011; **17**: 3012-3019 [PMID: 21799647 DOI: 10.3748/wjg.v17.i25.3012]

76   **Guaraldi G**, Besutti G, Stentarelli C, Zona S, Nocetti L, Loria P, Ballestri S, Losi L, Torricelli P, Ligabue G. Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. *Antivir Ther* 2012; **17**: 965-971 [PMID: 22766513 DOI: 10.3851/IMP2228]

77   **Koelblinger C**, Krššák M, Maresch J, Wrba F, Kaczirek K, Gruenberger T, Tamandl D, Ba-Ssalamah A, Berger-Kulemann V, Weber M, Schima W. Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0 T before hepatic surgery: reliable enough for making clinical decisions? *Eur J Radiol* 2012; **81**: 2990-2995 [PMID: 22770582 DOI: 10.1016/j.ejrad.2012.01.025]

78   **Bhat V**, Velandai S, Belliappa V, Illayraja J, Halli KG, Gopalakrishnan G. Quantification of Liver Fat with mDIXON Magnetic Resonance Imaging, Comparison with the Computed Tomography and the Biopsy. *J Clin Diagn Res* 2017; **11**: TC06-TC10 [PMID: 28892997 DOI: 10.7860/JCDR/2017/26317.10234]

79   **Noureddin M**, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C, Loomba R. Utility of magnetic resonance imaging *vs* histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. *Hepatology* 2013; **58**: 1930-1940 [PMID: 23696515 DOI: 10.1002/hep.26455]

80   **Schwimmer JB**, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, Lam J, Hooker JC, Hamilton G, Fontanesi J, Sirlin CB. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. *Hepatology* 2015; **61**: 1887-1895 [PMID: 25529941 DOI: 10.1002/hep.27666]

81   **Middleton MS**, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB; NASH Clinical Research Network. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. *Gastroenterology* 2017; **153**: 753-761 [PMID: 28624576 DOI: 10.1053/j.gastro.2017.06.005]

82   **Pickhardt PJ**, Graffy PM, Reeder SB, Hernando D, Li K. Quantification of Liver Fat Content With Unenhanced MDCT: Phantom and Clinical Correlation With MRI Proton Density Fat Fraction. *AJR Am J Roentgenol* 2018; **211**: W151-W157 [PMID: 30016142 DOI: 10.2214/AJR.17.19391]

83   **Guo Z**, Blake GM, Li K, Liang W, Zhang W, Zhang Y, Xu L, Wang L, Brown JK, Cheng X, Pickhardt PJ. Liver Fat Content Measurement with Quantitative CT Validated against MRI Proton Density Fat Fraction: A Prospective Study of 400 Healthy Volunteers. *Radiology* 2020; **294**: 89-97 [PMID: 31687918 DOI: 10.1148/radiol.2019190467]